ArticleESMO real world data and digital oncology2026
Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small-cell lung cancer after definitive chemoradiation.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Since the 2018 Food and Drug Administration approval of immunotherapy (IO) for consolidative therapy in stage III non-small-cell lung cancer (NSCLC), real-world uptake across racial and socioeconomic groups remains poorly characterized. This study evaluated IO utilization patterns after definitive chemoradiation (CRT) in a diverse national cohort. Materials and methods: A retrospective analysis was carried out using the National Cancer Database for patients aged ≥18 years diagnosed with stage III NSCLC from 2018 to 2021. Inclusion criteria included receipt of ≥60 Gy of radiation in ≥30 fractions, and IO administered 50-150 days from CRT initiation. Surgical cases were excluded. Social determinants of health included race, ethnicity, insurance type, treatment facility, Charlson-Deyo comorbidity index, high school graduation rate (HSGR), income, sex, and age. Odds ratios (ORs) were calculated using univariable and multivariable logistic regression, and multicollinearity was tested via Cramér V. Results: Among 25 746 patients, 21 848 were white, 3236 black, 558 Asian, 104 American Indian or Alaska Native, and 620 Hispanic. Univariable analysis showed lower IO use among black (OR 0.86), Hispanic (OR 0.72), Mexican (OR 0.45), and South Asian (OR 0.48) patients, those with Medicare (OR 0.94), treated at community sites (OR 0.88), and from lower HSGR and income areas (ORs ≤ 0.90), all Conclusion: Disparities in IO receipt persist after CRT for stage III NSCLC in the post-IO era, highlighting the need to address systemic barriers to equitable cancer care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.